Tradestie Institutional Equity Comparison Engine
BHVN vs SRPT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BHVN Overall Edge
BHVN Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biohaven Ltd. (BHVN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while SRPT counters with relative strength in Valuation. Fundamentally, BHVN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SRPT at 10.8x Forward P/E and -0.4% operating margin (-4.5% YoY). In options structure, BHVN sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro) against SRPT sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
SRPT
BHVN N/M vs SRPT 10.8x Fwd P/E
Growth & Margin Winner
BHVN
Op Margin 0.0% vs -0.4% ยท YoY +0.0% vs -4.5%
Momentum & Technical Winner
BHVN
1Y +72.1% vs -15.0% ยท 52W Pos 59% vs 5%
Options & Structure Winner
BHVN
CONSOLIDATION (18th %ile IV) vs BREAKDOWN (7th %ile IV)
BHVN
NYSE
Biohaven Ltd.
Pharmaceutical Preparations
$13.90
+0.62% 1D
Market Cap
$2.1B
1M Return
+28.99%
1Y Return
+72.09%
Forward P/E
N/M
Unified AI Score
42.1 / 100
HOLD
Tech 15.0
Fund 42.0
Flow 68.0
Mom 50.0
SRPT
NASDAQ
Sarepta Therapeutics,, Inc. Common Stock
Pharmaceutical Preparations
$15.14
-5.76% 1D
Market Cap
$1.7B
1M Return
-11.44%
1Y Return
-15.02%
Forward P/E
10.8x
Unified AI Score
37.8 / 100
SELL
Tech 32.0
Fund 51.0
Flow 71.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BHVN +72.09%
SRPT -15.02%
Spread: +87.11 pp (BHVN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BHVN TTM Op. Margin: 0.0%
SRPT TTM Op. Margin: -0.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHVN vs SRPT. Trailing 12-month operating profitability (BHVN 0.0% vs SRPT -0.4%) and valuation multiples (BHVN N/M vs SRPT 10.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BHVN | SRPT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $1.7B | Larger Scale | BHVN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | 10.8x | Lower Multiple | SRPT |
| Revenue Growth (YoY) Growth | +0.0% | -4.5% | Higher Growth | BHVN |
| Operating Margin (TTM) Profitability | 0.0% | -0.4% | Higher Margin | BHVN |
| Net Profit Margin Profitability | 0.0% | -5.9% | Higher Margin | BHVN |
| Return on Equity (ROE) Capital Efficiency | -799.5% | -8.1% | Higher ROE | SRPT |
| 52-Week Range Position Momentum | 59% ($8โ$18) | 5% ($15โ$25) | Stronger Trend | BHVN |
| Beta / 30D Volatility Risk Regime | 1.41ฮฒ ยท 111% Vol | 1.47ฮฒ ยท 58% Vol | Lower Realized Risk | SRPT |
| Unified Institutional Score Composite Signal | 42.1 / 100 (HOLD) | 37.8 / 100 (SELL) | Higher Composite | BHVN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BHVN vs SRPT Buy Guide
BHVN
CONSOLIDATION
91d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
18th %ile
IV Regime
Compressed (<25th %ile)
SRPT
BREAKDOWN
52d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
7th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BHVN nor SRPT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.